Article
Medicine, General & Internal
Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julian Panes, Laurent Peyrin-Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens
Summary: Subcutaneous risankizumab is a safe and effective treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option that might change the future course of the disease.
Article
Oncology
Florence Duffaud, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, Olivier Mir, Sophie Piperno-Neumann, Christine Chevreau, Corinne Delcambre, Francois Bertucci, Pascaline Boudou-Rouquette, Mathilde Cancel, Christophe Perrin, Esma Saada-Bouzid, Laure Monard, Camille Schiffler, Loic Chaigneau, Alice Hervieu, Olivier Collard, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Jean-Yves Blay
Summary: This multi-cohort trial investigated the efficacy and safety of regorafenib for advanced sarcomas of bone origin, focusing on patients with metastatic or locally advanced chondrosarcoma progressing after prior chemotherapy. While the primary endpoint was not statistically met in this small randomized cohort, there is modest evidence suggesting that regorafenib may slow disease progression in patients with metastatic CS after prior chemotherapy failure.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Brad H. Rovin, Y. K. Onno Teng, Ellen M. Ginzler, Cristina Arriens, Dawn J. Caster, Juanita Romero-Diaz, Keisha Gibson, Joshua Kaplan, Laura Lisk, Sandra Navarra, Samir V. Parikh, Simrat Randhawa, Neil Solomons, Robert B. Huizinga
Summary: This study evaluated the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing a superior complete renal response rate with voclosporin in combination with MMF and low-dose steroids compared to MMF and low-dose steroids alone. The safety profile was comparable between the two groups. This finding represents an important advancement in the treatment of patients with active lupus nephritis.
Article
Rheumatology
Pascal Richette, Augustin Latourte, Jeremie Sellam, Daniel Wendling, Muriel Piperno, Philippe Goupille, Yves-Marie Pers, Florent Eymard, Sebastien Ottaviani, Paul Ornetti, Rene-Marc Flipo, Bruno Fautrel, Olivier Peyr, Jean Pierre Bertola, Eric Vicaut, Xavier Chevalier
Summary: The study found that tocilizumab was not more effective than placebo in relieving pain in patients with hand osteoarthritis. Apart from the primary endpoint, there were no significant differences in secondary outcomes between the tocilizumab group and the placebo group.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Medicine, General & Internal
Andrew W. Horne, Stephen Tong, Catherine A. Moakes, Lee J. Middleton, W. Colin Duncan, Ben W. Mol, Lucy H. R. Whitaker, Davor Jurkovic, Arri Coomarasamy, Natalie Nunes, Tom Holland, Fiona Clarke, Ann M. Doust, Jane P. Daniels
Summary: This study evaluated whether oral gefitinib in combination with methotrexate is more effective than methotrexate alone in the treatment of tubal ectopic pregnancy. The results showed that oral gefitinib does not offer clinical benefit over methotrexate and increases minor adverse reactions.
Article
Rheumatology
Renaud Felten, Valerie Devauchelle-Pensec, Raphaele Seror, Pierre Duffau, David Saadoun, Eric Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, Arsene Mekinian, Olivier Vittecoq, Jean-Marie Berthelot, Emanuelle Dernis, Veronique Le Guern, Philippe Dieude, Claire Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, Pierre Kieffer, Francois Maurier, Azeddine Dellal, Stephanie Rist, Emmanuel Andres, Anne Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cecile Arnold, Mira Y. Tawk, Ouafaa Aberkane, Lise Holterbach, Patrice Cacoub, Alain Saraux, Xavier Mariette, Nicolas Meyer, Jacques-Eric Gottenberg
Summary: This study aimed to demonstrate the efficacy of targeting interleukin 6 receptor in patients with primary Sjogren's syndrome-related systemic complications. However, the results showed that over 24 weeks of treatment, tocilizumab did not improve systemic involvement and symptoms in patients with primary Sjogren's syndrome.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Oncology
Dean A. Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G. Hanna, Kayleigh Hill, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Aarti Gaba, Liz Darlison, Peter Wells-Jordan, Cathy Richards, Charlotte Poile, Jason F. Lester, Gareth Griffiths
Summary: The study evaluated the efficacy and safety of nivolumab in patients with pleural or peritoneal malignant mesothelioma who had progressed following platinum-based chemotherapy. Nivolumab showed improved progression-free survival and overall survival compared to placebo in these patients, with manageable treatment-related adverse events. The results suggest that nivolumab might be a beneficial treatment for patients with malignant mesothelioma who have progressed on first-line therapy.
Article
Medical Informatics
Chantal M. den Bakker, Frederieke G. Schaafsma, Esther C. J. Consten, Steven E. Schraffordt Koops, Eva van der Meij, Peter M. van de Ven, Hendrik J. Bonjer, Judith A. F. Huirne, Johannes R. Anema
Summary: This study aimed to assess the impact of a personalised eHealth programme on patients' return to normal activities after major abdominal surgery. The results showed that patients who received the eHealth intervention had a 13-day earlier return to normal activities compared to those who received standard care.
LANCET DIGITAL HEALTH
(2023)
Article
Clinical Neurology
Pedro M. Machado, Michael P. McDermott, Thomas Blaettler, Claus Sundgreen, Anthony A. Amato, Emma Ciafaloni, Miriam Freimer, Summer B. Gibson, Sarah M. Jones, Todd D. Levine, Thomas E. Lloyd, Tahseen Mozaffar, Aziz Shaibani, Matthew Wicklund, Anders Rosholm, Tim Dehli Carstensen, Karen Bonefeld, Anders Norkaer Jorgensen, Karina Phonekeo, Andrew J. Heim, Laura Herbelin, Richard J. Barohn, Michael G. Hanna, Mazen M. Dimachkie
Summary: Arimoclomol did not show efficacy in individuals with inclusion body myositis compared to placebo, but it had an acceptable safety profile. This study provides valuable data on disease progression for future clinical trial designs in inclusion body myositis.
Article
Gastroenterology & Hepatology
Evan S. Dellon, Kathryn A. Peterson, Benjamin L. Mitlyng, Alina Iuga, Christine E. Bookhout, Lindsay M. Cortright, Kacie B. Walker, Timothy S. Gee, Sarah J. McGee, Brenderia A. Cameron, Joseph A. Galanko, John T. Woosley, Swathi Eluri, Susan E. Moist, Ikuo Hirano
Summary: This study aimed to determine the efficacy of mepolizumab in improving dysphagia symptoms and reducing esophageal eosinophil counts in EoE. The results showed that mepolizumab significantly decreased symptoms and eosinophil counts within 3 months, but longer treatment did not yield additional improvement.
Article
Respiratory System
Dave Singh, Jutta Beier, Carol Astbury, Maria G. Belvisi, Carla A. Da Silva, Alexandra Jauhiainen, Eulalia Jimenez, Alejhandra Lei, Sofia Necander, Jaclyn A. Smith, Ulrika Wahlby Hamren, Wenjing Xin, Ioannis Psallidas
Summary: Navafenterol, a new bronchodilator for COPD treatment, was found to improve lung function and alleviate COPD symptoms similar to an established bronchodilator, with good safety profile.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Medicine, General & Internal
William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D'Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan
Summary: Etrasimod, a selective S1P receptor modulator, demonstrated efficacy and safety as an induction and maintenance therapy for patients with moderately to severely active ulcerative colitis. The trials showed a higher proportion of patients achieving clinical remission with Etrasimod compared to placebo at both induction and maintenance periods. This novel treatment option has the potential to address unmet needs in ulcerative colitis patients.
Article
Oncology
Bradley J. Monk, Takafumi Toita, Xiaohua Wu, Juan C. Vazquez Limon, Rafal Tarnawski, Masaki Mandai, Ronnie Shapira-Frommer, Umesh Mahantshetty, Maria del Pilar Estevez-Diz, Qi Zhou, Sewanti Limaye, Francisco J. Ramirez Godinez, Christina Oppermann Kussler, Szilvia Varga, Natalia Valdiviezo, Daisuke Aoki, Manuel Leiva, Jung-Yun Lee, Raymond Sulay, Yulia Kreynina, Wen-Fang Cheng, Felipe Rey, Yi Rong, Guihao Ke, Sophie Wildsmith, Andrew Lloyd, Hannah Dry, Ana Tablante Nunes, Jyoti Mayadev
Summary: This study assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. The results showed that the addition of durvalumab did not significantly improve progression-free survival, but it may have potential efficacy in patients with high tumoral PD-L1 expression.
Article
Medicine, General & Internal
Nilufar Mohebbi, Alexander Ritter, Anna Wiegand, Nicole Graf, Suzan Dahdal, Daniel Sidler, Spyridon Arampatzis, Karine Hadaya, Thomas F. Mueller, Carsten A. Wagner, Rudolf P. Wuethrich
Summary: This study examined the effects of sodium bicarbonate treatment on graft function in kidney transplant recipients. The results showed that treatment with sodium bicarbonate for two years did not affect the decline in estimated glomerular filtration rate (GFR). Therefore, sodium bicarbonate treatment is not generally recommended for preserving GFR in kidney transplant recipients with chronic kidney disease and metabolic acidosis.
Article
Medicine, General & Internal
Renhua Lu, Le-Yi Gu, Weiming Zhang, Yongping Guo, Xiujuan Zang, Yan Zhou, Ling Yu, Shuting Pan, Huihua Pang, Shang Liu, Kewei Xie, Ping Li, Xiaojun Zeng, Yifei Lu
Summary: Cognitive impairment is a common complication in maintenance haemodialysis patients, with oxidative stress being one of the main mechanisms. Supplementation of thiamine and folic acid may improve cognitive function.